| |
| |
|
| Insider
Information: |
Reese David M |
| Relationship: |
EVP & Chief Technology... |
| City: |
Thousand Oaks |
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
60,666 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$16,378,607 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
60,666 |
|
|
| Total
Value |
$16,378,607 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amgen Inc |
AMGN |
EVP & Chief Technology... |
2024-03-18 |
60,666 |
2018-11-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMGN |
Amgen Inc |
EVP & Chief Technology Officer |
• • – |
2024-03-18 |
4 |
D |
$268.87 |
$1,667,532 |
D/D |
(6,202) |
60,666 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP & Chief Technology Officer |
• • – |
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
12,407 |
66,653 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2023-11-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
165 |
54,164 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2023-05-05 |
4 |
D |
$231.89 |
$137,743 |
D/D |
(594) |
54,114 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$193,259 |
D/D |
(819) |
54,708 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,814 |
55,527 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$159,667 |
D/D |
(666) |
51,713 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2023-03-17 |
4 |
D |
$234.57 |
$933,119 |
D/D |
(3,978) |
52,379 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,947 |
56,167 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2022-11-02 |
4 |
D |
$272.06 |
$663,826 |
D/D |
(2,440) |
48,136 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2022-05-05 |
4 |
D |
$236.10 |
$135,758 |
D/D |
(575) |
50,307 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2022-05-03 |
4 |
D |
$230.92 |
$177,808 |
D/D |
(770) |
50,882 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2022-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,897 |
51,652 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2022-04-27 |
4 |
D |
$249.87 |
$45,976 |
D/D |
(184) |
47,755 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$1,178,121 |
D/D |
(4,995) |
47,939 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,989 |
52,714 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-11-02 |
4 |
D |
$209.74 |
$459,750 |
D/D |
(2,192) |
42,593 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$178,532 |
D/D |
(745) |
44,472 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-05-01 |
4 |
D |
$239.64 |
$265,761 |
D/D |
(1,109) |
45,217 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,006 |
46,326 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-04-27 |
4 |
D |
$255.52 |
$44,460 |
D/D |
(174) |
42,320 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-03-19 |
4 |
D |
$244.42 |
$342,432 |
D/D |
(1,401) |
42,494 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,803 |
43,715 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-02-16 |
4 |
D |
$237.21 |
$272,080 |
D/D |
(1,147) |
40,912 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research and Development |
• • – |
2021-02-16 |
4 |
OE |
$54.69 |
$125,787 |
D/D |
2,300 |
42,059 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
